Evaxion Biotech A/S (EVAX) Revenue History
Annual and quarterly revenue from 2018 to 2025
Compound Annual Growth Rate (CAGR)
Loading revenue history...
EVAX Revenue Growth
EVAX Revenue Analysis (2018–2025)
As of May 8, 2026, Evaxion Biotech A/S (EVAX) generated trailing twelve-month (TTM) revenue of $7.6 million, reflecting significant decline in growth of -81.9% year-over-year. The most recent quarter (Q4 2025) recorded $22,040 in revenue, down 99.7% sequentially.
Looking at the longer-term picture, EVAX's historical revenue data shows various trends over time. The company achieved its highest annual revenue of $7.6 million in 2025, representing a new all-time high.
When compared to Healthcare sector peers including NEON (-33.7% YoY), NKTR (-43.9% YoY), and IOVA (+34.3% YoY), EVAX has underperformed the peer group in terms of revenue growth. Compare EVAX vs NEON →
EVAX Revenue vs Peers
Revenue metrics vs comparable public companies
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
| EVAXCurrent | $8M | -81.9% | - | -122.7% | |
 NEON | $2M | -33.7% | -19.2% | -391.5% | |
 NKTR | $55M | -43.9% | -18.4% | -236.8% | |
 IOVA | $264M | +34.3% | - | -153.1% | |
 GILD | $29.4B | +3.5% | +3.6% | 40.1% |
EVAX Historical Revenue Data (2018–2025)
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | $7.6M | +125.8% | $7.5M | 99.7% | $-9,262,262 | -122.7% |
| 2024 | $3.3M | +4480.8% | $3.3M | 100.0% | $-14,732,000 | -440.6% |
| 2023 | $73K | - | $73K | 100.0% | $-22,197,000 | -30406.8% |
| 2022 | $0 | - | $0 | - | $-25,264,000 | - |
| 2021 | $0 | - | $0 | - | $-25,834,000 | - |
| 2020 | $0 | - | $0 | - | $-16,568,000 | - |
| 2019 | $0 | - | $-80,984 | - | $-11,360,761 | - |
| 2018 | $0 | - | $-73,928 | - | $-5,627,000 | - |
See EVAX's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs EVAX Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare EVAX vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonEVAX — Frequently Asked Questions
Quick answers to the most common questions about buying EVAX stock.
Is EVAX's revenue growth accelerating or slowing?
EVAX revenue declined -81.9% year-over-year, contrasting with the 5-year CAGR of N/A. TTM revenue fell to $8M. This reverses the prior growth trend.
What is EVAX's long-term revenue growth rate?
Evaxion Biotech A/S's 5-year revenue CAGR of N/A reflects the variable expansion pattern. Current YoY growth of -81.9% is below this long-term average.
How is EVAX's revenue distributed by segment?
EVAX reports revenue by product line and geographic region. Annual and quarterly breakdowns from 2018-2025 are available for download. Segment mix reveals concentration and diversification trends.